Spots Global Cancer Trial Database for Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Official Title: A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature
Study ID: NCT02982694
Study Description
Brief Summary: The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an international, open-label single arm (non-randomized), one-stage phase II trial.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
KU Leuven, Leuven, , Belgium
Ospedale Niguarda CA Granda, Milano, , Italy
Second University of Naples, Naples, , Italy
The Netherlands Cancer Institute, Amsterdam, , Netherlands
Institut Català d'Oncologia, Barcelona, , Spain
Vall d'Hebron Institute of Oncology, Barcelona, , Spain
Fundación Investigación Clínico de Valencia, Valencia, , Spain
Contact Details
Name: Josep Tabernero Caturla, Prof
Affiliation: Vall d'Hebron Institute of Oncology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
